Cargando…
779. Impact of updated IDSA practice guidelines on the treatment of Clostridium difficile infections in the United States
BACKGROUND: IDSA published updated practice guidelines for C. difficile infections (CDI) in February 2018. Since publication of previous CDI guidelines in2010, randomized clinical trials (RCTs) have demonstrated benefit of oral (po) vancomycin or fidaxomicin over metronidazole in at least some types...
Autores principales: | Clancy, Cornelius J, Nguyen, Minh-Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811244/ http://dx.doi.org/10.1093/ofid/ofz360.847 |
Ejemplares similares
-
1987. Impact of Updated IDSA Clostridium difficile Guidelines on the use of Fidaxomicin in a Large Health System
por: Bariola, J Ryan, et al.
Publicado: (2019) -
1655 Lack of Adherence to SHEA-IDSA Treatment Guidelines for Severe Clostridium difficile Infection is Associated with Increased Mortality
por: Patel, Ishan, et al.
Publicado: (2014) -
Discordance of SHEA/IDSA Clostridium difficile Disease Severity Scale in Solid Organ Transplant Patients
por: Lee, Tiffany, et al.
Publicado: (2017) -
383. Assessing the 2021 IDSA Treatment Clostridioides difficile Guidelines in a Small, Community Hospital
por: Barner, Amanda, et al.
Publicado: (2022) -
779. Clostridiodes difficile: Is it time for surveillance! Cost-benefit analysis
por: Yassin, Mohamed, et al.
Publicado: (2020)